Osteosarcoma cell lines display variable individual reactions on wildtype p53 and Rb tumour-suppressor transgenes

Journal of Gene Medicine

Volumn 7, Issue 4, 2005, Pages 407-419

  Hellwinkel, Olaf J C ^a   Müller, Jürgen ^a   Pollman, Annika ^a   Kabisch, Hartmut ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Gene therapy; Osteosarcoma; p53; Rb; Retinoblastoma; Tumour suppressor

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; DOXORUBICIN; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; DRUG EFFICACY; DRUG POTENTIATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; OSTEOSARCOMA; PRIORITY JOURNAL; STRAIN DIFFERENCE; TRANSGENE; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTIVITY; WILD TYPE;

ADENOVIRIDAE; BLOTTING, WESTERN; CELL LINE, TUMOR; GENES, P53; GENES, RETINOBLASTOMA; HUMANS; OSTEOSARCOMA; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSGENES;

EID: 17544363106     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.684     Document Type: Article

References (31)

1. Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21: 2011-2018.
2. Scholz RB, Christiansen H, Kabisch H, et al. Molecular markers in the evaluation of bone neoplasms. In Pathology of Bone and Joint Neoplasms, Helliwell TR (ed). W.B. Saunders Co.: Philadelphia, 1999; 79-105.
3. Wadayama BI, Togushida J, Shimizu T, et al. Mutation spectrum of the retinoblastoma gene in osteosarcoma. Cancer Res 1994; 54: 3042-3048.
4. Chang EH, Pirollo KF, Booker KB. Tp53 gene therapy: a key to modulating resistance to anticancer therapies? Mol Med Today 2000; 6: 358-364.
5. Roth JA, Swisher SG, Meyn RE. p53 tumor suppressor gene therapy for cancer. Oncology (Huntingt) 1999; 13: 148-154.
6. Kawashima H, Ogose A, Yoshizawa T, et al. Expression of the coxsackievirus and adenovirus receptor in musculoskeletal tumors and mesenchymal tissues: efficacy of adenoviral gene therapy for osteosarcoma. Cancer Sci 2003; 94: 70-75.
7. Densmore CL, Kleinerman ES, Gautam A, et al. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther 2001; 8: 619-627.
8. Song SU, Boyce FM. Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy (p53) and chemotherapy (adriamycin). Exp Mol Med 2001; 33: 46-53.
9. Honoki K, Tsujiuchi T, Tsutsumi M, et al. Possible involvement of bcl-2 suppression in wild-type p53 gene-dependent cell growth repression in rat osteosarcoma cells. Toxicol Pathol 2000; 28: 575-579.
10. Tsuchiya H, Mori Y, Ueda Y, et al. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma. Anticancer Res 2000; 20: 235-242.
11. Ko SC, Cheon J, Kao C, et al. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res 1996; 56: 4614-4619.
12. Ip SM, Huang TG, Yeung WS, et al. pRb-expressing adenovirus Ad5-Rb attenuates the p53-induced apoptosis in cervical cancer cell lines. Eur J Cancer 2001; 37: 2475-2483.
13. Xu HJ, Zhou Y, Seigne J, et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 1996; 56: 2245-2249.
14. Wick M, Burger C, Brusselbach S, et al. Identification of serum-inducible genes: different patterns of gene regulation during G0 → S and G1 → S progression. J Cell Sci 1994; 107(Pt 3): preceding table of contents.
15. Hellwinkel OJ, Muller A, Struve D, et al. Influence of androgens and age on androgen receptor and 5 alpha-reductase II transcription. Eur J Endocrinol 2000; 143: 217-225.
16. Block A, Puls F, Müller J, et al. Highly suppressible expression of single-chain interleukin-12 by doxycycline adenoviral infection with a single-vector Tet-regulatory system. J Gene Med 2003; 5: 190-200.
17. Hitt M, Bett A, Prevec L, et al. Construction and propagation of human adenovirus vectors. In Cell Biology; a Laboratory Handbook (2nd edn), vol. 1, Celis JE (ed). Academic Press: San Diego, 1998; 500-512.
18. Goodman and Gilman's: The Pharmacological Basis of Therapeutics (8th edn). Pergamon Press: New York, 1990.
19. Yap DBS, Hsieh JK, Chan FSG, et al. mdm2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene 1999; 18: 7681-7689.
20. Florenes VA, Maelandsmo GM, Forus A, et al. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 1994; 86: 1297-1302.
21. Sionov RV, Haupt Y. The cellular response to p53: the decision between life and death. Oncogene 1999; 18: 6145-6157.
22. Wu XW, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci U S A 1994; 91: 3602-3606.
23. Kowalik TF, DeGregori J, Leone G, et al. E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ 1998; 9: 113-118.
24. Haas-Kogan DA, Kogan SC, Levi D, et al. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 1995; 14 461-472.
25. Scheel C, Schaefer KL, Jauch A, et al. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene 2001; 20: 3835-3844.
26. Scheel C, Poremba C. Telomere lengthening in telomerase-negative cells: the ends are coming together. Virchows Arch 2002; 440: 573-582.
27. Bougeret C, Virone-Oddos A, Adeline E, et al. Cancer gene therapy mediated by CTS1, a p53 derivative: advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2. Cancer Gene Ther 2000; 7: 789-798.
28. Knudsen ES, Wang JYJ. Dual mechanisms for the inhibition of E2F binding to Rb by cyclin-dependent kinase-mediated Rb phosphorylation. Mol Cell Biol 1997; 17: 5771-5783.
29. Romano JW, Ehrhart JC, Duthu A, et al. Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line. Oncogene 1989; 4: 1483-1488.
30. Chandar N, Billig B, McMaster J, et al. Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer 1992; 65: 208-214.
31. Ewen ME, Sluss HK, Sherr CJ, et al. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993; 73: 487-497.